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A B S T R A C T
We describe the generation and characterization of two human induced pluripotent stem cell (hiPSCs) lines reprogrammed from myoblasts and from peripheral blood
mononuclear cells (PBMCs) from the same donor. The donor was free of neuromuscular disorders, male and 18 years of age. For reprogramming we used Sendai-virus
delivery of the four Yamanaka factors. The pluripotent identity of the hiPSC lines was confirmed by the expression of pluripotency markers and their capacity to
differentiate into all three germ layers. These hiPSCs constitute a tool to study tissue of origin specific differences in the identity of hiPSCs.
1. Resource Table




Alternative names of stem
cell lines
N/A
Institution Max Delbrück Center for Molecular Medicine, Berlin,
Germany





Type of cell lines iPSCs
Origin Human
Cell Source Myoblasts (MDCi014-A)
Peripheral Blood Mononuclear Cells (PBMCs)
(MDCi014-B)
Clonality Mixed
Method of reprogramming Sendai-virus (OCT3/4, SOX2, KLF4, c-Myc)
Multiline rationale hiPSCs generated from myoblasts and PBMCs from the
same donor
Gene modification NO
Type of modification N/A
Associated disease No disease reported
Gene/locus N/A
Method of modification N/A






Date archived/stock date 01/2020
07/2020
Cell line repository/bank https://hpscreg.eu/cell-line/MDCi014-A
https://hpscreg.eu/cell-line/MDCi014-B




Several studies have shown that the cell type of origin can influence
the epigenetic profile and the differentiation capacity of hiPSC into
different tissues. The question of what tissue source is optimal to gen-
erate hiPSC for specific downstream applications is highly relevant and
yet to be categorically answered.
3. Resource details
The tissue of origin of iPSCs has been shown to influence their
epigenetic profile (Kim et al., 2011) and differentiation capacity into
different tissue cell types (Bar-Nur et al., 2011; Sanchez-Freire et al.,
2014). Understanding these tissue-of-origin-specific differences is fun-
damental to enhance the application of hiPSCs for e.g. disease model-
ling or cell therapies. In this study, we describe the generation of two
hiPSC lines generated from a donor free of neuromuscular disorders,
male and 18 years of age (see Table 1). One hiPSC line was
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reprogrammed from myoblasts and one from peripheral blood mono-
nuclear cells (PBMCs).
Myoblasts and PBMCs were reprogrammed using Sendai-virus de-
livery of the 4 Yamanaka factors, OCT3/4, SOX2, KLF4 and c-Myc. Each
hiPSC line was derived from a single colony that was isolated and ex-
panded after reprogramming. Both hiPSC lines were tested negative for
the presence of remaining Sendai-virus particles by RT-PCR in passages
13–15 (Suppl. Fig. S1). The master cell bank was generated for all lines
in passage 15–17 and was proven to be negative for any mycoplasma
contamination by RT-qPCR (Fig. 1E). Both hiPSC lines, cultured in
mTeSR™1 medium on Matrigel-coated plates, show well-defined colony
borders and packed colony morphology with no signs of spontaneous
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
MDCi014-A MDCi014-A male 18 Caucasian N/A N/A
MDCi014-B MDCi014-B male 18 Caucasian N/A N/A
Fig. 1. Characterization of the generated myoblast- (MDCi014-A) and PBMC-derived (MDCi014-B) hiPSCs.
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differentiation (Fig. 1B). Immunofluorescence analysis showed the ex-
pression of markers for undifferentiated pluripotent stem cells as oc-
tamer-binding transcription factor 3/4 (OCT3/4), sex determining re-
gion Y-box 2 (SOX2), NANOG and tumour rejection antigen (TRA-1–60)
(Fig. 1A). Additionally, the purity of the pluripotent cell populations
was confirmed by quantifying the percentage of cells positive for OCT3/
4 (99.6%/99.4%), NANOG (99.8%/99.7%), TRA-1–60 (97.8%/96.4%)
and stage specific embryonic antigen 4 (SSEA4) (98.7%/98.4%) via
flow cytometry. Additionally, the differentiation marker stage specific
embryonic antigen 1 (SSEA1) was expressed in 0.1% of the cells in both
hiPSC lines, thus confirming pluripotent cell states (Fig. 1C, Table 2,
raw data available at hPSCreg). The three-germ layer differentiation
capacity was tested via teratoma formation assay. Histopathological
examination of the teratoma tissues confirmed the generation of tissues
of mesodermal, ectodermal and endodermal origin for both hiPSC lines
(Fig. 1D). Single nucleotide polymorphism (SNP)- analysis confirmed
typical karyotypes without numerical chromosomal abnormalities for
M_hiPSCs and B_hiPSCs and the corresponding myoblasts of origin.
Regions that show differences to the human reference genome like in-
sertions (green), deletions (red) or LOH (loss of heterozygosity) are
depicted on the left side of each chromosome as colored bars with no
areas of insertions or deletions above 1.2 MB. Most abnormalities are
already present in the parental cell populations and minor abnormal-
ities may be attributed to the comparison to the standard human
genome (Fig. 1F). Short tandem repeat (STR)- analysis of 16 genomic
loci showed identical DNA profiles between the generated hiPSC lines
and the corresponding donor-derived myoblast sample (available with
journal).
In conclusion we generated and fully characterised two hiPSC lines
reprogrammed from myoblasts and PBMCs of the same donor. Those
lines can be used to investigate the influence of tissues of origin on the
characteristics of hiPSCs.
4. Materials and methods
4.1. Reprogramming
Myoblasts were isolated from muscle biopsy specimen and PBMCs
from whole blood. Both were cultured in 21% O2, 5% CO2, 37 °C, 95%
rH. For reprogramming, Sendai-virus delivery of OCT3/4, SOX2, KLF4
and c-Myc (CytoTune™-iPS 2.0 Sendai Reprogramming Kit, Invitrogen,
Fusaki et al., 2009) was used. Briefly, 5x104 myoblasts were seeded on
Matrigel (concentration according to the dilution factor as specified for
each lot number) in Skeletal Muscle Cell Growth Medium (SMCGM,
ProVitro) + Polybrene (10 µg/ml) + Sendai virus mix. After 24 h 50%
fresh SMCGM was added. The next day medium was exchanged for
fresh SMCGM+ Sodium Butyrate (200 µM) + Ascorbic acid (64 µg/µl)
and exchanged every other day. Accordingly, 3x105 PBMCs were in-
fected with the Sendai-virus mix in PBMC medium (StemPro™-34 SFM
medium + supplement, L-Glutamine (2 mM), SCF (100 ng/ml), FLT-3
(100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), Epo (2U/ml)) + Poly-
brene. Sendai-virus was removed by centrifugation on the next day and
50% medium was exchanged every other day using fresh PBMC
medium + Sodium Butyrate + Ascorbic acid. When hiPSC colonies
showed well-defined borders medium was changed to mTeSR™1
(Stemcell Technologies) and cells were transferred to 5% O2, 5% CO2,
37 °C, 95% rH.
4.2. Test for the absence of Sendai virus
Absence of Sendai-virus particles was analysed by RT-PCR
(Hildebrand et al., 2016) using DreamTaq Green PCR Master Mix
(Thermo Fisher Scientific) together with the primers listed in Table 3
following this program: 95 °C 5 min, 35 cycles: 95 °C 30 sec, 55 °C
30 sec, 72 °C 30 sec and finally 72 °C for 10 min. PCR products were
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Phase contrast microscopy Normal Fig. 1 panel B






Fig. 1 panel A












Fig. 1 panel C
Raw data available at
hPSCreg
Genotype Karyotype (Single Nucleotide Polymorphism
Analysis (SNPs))
46, XX No numerical aberrations
No large deletions/insertions
Total number of markers: 962,215
Fig. 1 panel F
Identity STR analysis Identity of myoblast- and PBMC-derived hiPSCs confirmed
comparing the hiPSCs against the primary myoblasts of each
donor





Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR, all negative Fig. 1 panel E
Differentiation potential Teratoma formation Formation of all three germ layers confirmed by histopathological
analysis for all samples
Fig. 1 panel D




Blood group genotyping N/A
HLA tissue typing N/A
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analysed using a 2% agarose gel.
4.3. hiPSC culture
hiPSCs were cultured in mTeSR™1 medium (Stemcell Technologies)
on Matrigel-coated 6-well plates at 5% O2. Cells were passaged routi-
nely at a ratio of 1:10 every 3 days using 0.5 mM PBS/EDTA.
Mycoplasma was tested using the Venor® GeM qOneStep kit (Minerva
Biolabs).
4.4. Immunofluorescence
hiPSCs grown on Matrigel-coated 8-well IbiTreat slides (Ibidi) were
fixed with 3.7% Formaldehyde (10 min). Except TRA-1-60 staining, all
cells were permeabilized with 0.2% Trition X-100 (10 min) followed by
blocking with 1% BSA/PBS (1 h). Primary antibodies were diluted in
1% BSA/PBS and incubated over night at 4 °C followed by secondary
antibodies for 1 h in PBS at RT (Table 3). Confocal immunofluorescence
imaging was performed using the Laser Scan Microscope LSM 700 (Carl
Zeiss).
4.5. Flow cytometry
Single cells were labelled with conjugated antibodies (Table 3).
Surface marker (SSEA1, SSEA4 and TRA1-60) staining was performed
in unfixed cells by incubation with antibodies diluted in 0.5% BSA/PBS
(10 min, 4 °C, dark). Intracellular marker (OCT3/4, NANOG) were
stained by fixation/permeabilization solution (Miltenyi Biotec, 130-
093-142) (30 min, 4 °C, dark) followed by antibody incubation in
permeabilization buffer (Miltenyi Biotec, 130-093-142) (30 min, 4 °C,
dark). Analysis was done using the MACSQuant® AnalyzerVYB and
FlowJo v10.4.
4.6. Teratoma formation assay
2.5*106 hiPSCs in 100 µl PBS/Matrigel (1:1) were injected sub-
cutaneously into the flank of immunodeficient NOD.Cg-
PrkdcscidII2rgtm1Sug/JigTac mice (Taconic Biosciences). Animals were
sacrificed when tumour reached more than 1 cm3 or 8 weeks after
transplantation.
4.7. Single nucleotide polymorphism (SNP)- Karyotype
hiPSCs where karyotyped using the OMNI-EXPRESS-8v1.6 chip
(Illumina). Karyostudio 1.3 software was used based on the information
of GRCh36/hg18 dataset.
4.8. Short tandem repeat (STR)- analysis
hiPSCs identity was confirmed using myoblast samples of the cor-
responding donors. For analysis, the AmpFLSTR™ NGM SElect™ PCR
Amplification Kit (ThermoFisher Scientific) was used.
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